Literature DB >> 19036691

Trends in chemotherapy utilization for colorectal cancer.

Daniel Renouf1, Hagen Kennecke, Sharlene Gill.   

Abstract

BACKGROUND: Since 1990, significant advances have occurred in the adjuvant and metastatic treatment of colorectal cancer (CRC). Not all patients may be eligible for chemotherapy (CT), and the proportions and characteristics of patients who receive treatment are not well defined. In this study, treatment patterns of patients referred to the British Columbia Cancer Agency (BCCA) with early-stage colon cancer and metastatic CRC between 1990 and 2004 are described. PATIENTS AND METHODS: This study included patients with stage II or III colon cancer or stage IV CRC at presentation referred to the BCCA during a 1-year period for 3 time cohorts: 1990, 2000, and 2004. Patients were considered treated with CT if they received > or = 1 cycle of any CT for indication of the initial referral diagnosis.
RESULTS: A total of 1421 patients were included: stage II/III, n = 915; stage IV, n = 506. Chemotherapy utilization increased significantly from 1990 to 2004 for adjuvant CT (1990: 29%; 2000: 45%; 2004: 52%; P < .001) and for palliative CT (1990: 35%; 2000: 51%; 2004: 63%; P < .001). The proportion of patients with stage II disease treated with adjuvant CT dramatically increased (1990: 4%; 2000: 26%; 2004: 30%; P < .001). The use of palliative CT was significantly associated with male sex (P = .025). Among older patients, only 25% received adjuvant CT, and 31% received palliative CT.
CONCLUSION: In this population-based study, adjuvant and palliative CT utilization increased significantly between 1990 and 2004. The majority of patients aged > 70 years did not receive CT, and women appeared less likely to receive palliative CT. Such disparities in CT utilization require further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036691     DOI: 10.3816/CCC.2008.n.051

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  11 in total

1.  Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study.

Authors:  Howard J Lim; Sharlene Gill; Caroline Speers; Barbara Melosky; Jeff Barnett; Catherine Fitzgerald; Susan O'Reilly; Hagen Kennecke
Journal:  J Oncol Pract       Date:  2009-07       Impact factor: 3.840

2.  Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study.

Authors:  S Yousuf Zafar; Jennifer L Malin; Steven C Grambow; David H Abbott; Jane T Kolimaga; Leah L Zullig; Jane C Weeks; John Z Ayanian; Katherine L Kahn; Patricia A Ganz; Paul J Catalano; Dee W West; Dawn Provenzale
Journal:  Cancer       Date:  2012-09-12       Impact factor: 6.860

Review 3.  Research in cancer care disparities in countries with universal healthcare: mapping the field and its conceptual contours.

Authors:  Christina Sinding; Rachel Warren; Donna Fitzpatrick-Lewis; Jonathan Sussman
Journal:  Support Care Cancer       Date:  2014-08-14       Impact factor: 3.603

4.  Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

Authors:  Drew W Rasco; Jingsheng Yan; Yang Xie; Jonathan E Dowell; David E Gerber
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

5.  Better Late than Never? Adherence to Adjuvant Therapy Guidelines for Stage III Colon Cancer in an Underserved Region.

Authors:  Whitney Guerrero; Amy Wise; Garrett Lim; Lei Dong; Jim Wan; Jeremiah Deneve; Evan Glazer; Paxton Dickson; R Scott Daugherty; Martin Fleming; David Shibata
Journal:  J Gastrointest Surg       Date:  2017-11-08       Impact factor: 3.452

6.  Gender disparities in metastatic colorectal cancer survival.

Authors:  Andrew Hendifar; Dongyun Yang; Felicitas Lenz; Georg Lurje; Alexandra Pohl; Cosima Lenz; Yan Ning; Wu Zhang; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

7.  Differences between referred and nonreferred patients in cancer research.

Authors:  Jason Faulds; Colleen E McGahan; P T Phang; Manoj J Raval; Carl J Brown
Journal:  Can J Surg       Date:  2013-10       Impact factor: 2.089

8.  Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis.

Authors:  Daniel Rayson; Robin Urquhart; Martha Cox; Eva Grunfeld; Geoff Porter
Journal:  J Oncol Pract       Date:  2012-07       Impact factor: 3.840

9.  Trends in receiving chemotherapy for advanced cancer patients at the end of life.

Authors:  Hee Seung Lee; Kyeong Hyeon Chun; Dochang Moon; Hahn Kyu Yeon; Sanghoon Lee; SooHyeon Lee
Journal:  BMC Palliat Care       Date:  2015-03-13       Impact factor: 3.234

10.  Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo.

Authors:  Wei Shen; Chun-Yi Wang; Xue-Hu Wang; Zhong-Xue Fu
Journal:  J Exp Clin Cancer Res       Date:  2009-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.